LaylaBird Incyte (NASDAQ:INCY) is one of the leaders in the global Janus kinase inhibitors market. Investment thesis Over the past month and a half, the company's share price has increased by more than 20%, reflecting grown optimism among institutional and retail investors following its $750 million acquisition of Escient Pharmaceuticals and the announcement in mid-May that its Board of Directors had authorized a $2 billion share buyback plan. Source: TradingView In my estimation, the acquisition has al ...